Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To examine whether, after 52 weeks of oral administration of double-blind treatment, the absolute change from baseline in HbA1c level with dapagliflozin plus metformin is non-inferior to glipizide (sulphonylurea) plus metformin in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone. Objectives after the 52-week extension period: - To assess the same safety and tolerability parameters as for the first 52 weeks, over 104 weeks treatment - To assess the maintenance of efficacy of dapagliflozin plus metformin over 104 weeks of treatment
Critère d'inclusion
- Type 2 Diabetes